PharmaEssentia Corp., a leading biopharmaceutical company headquartered in Taiwan (TW), is dedicated to the development and commercialisation of innovative therapies for patients with rare diseases. Founded in 2003, the company has made significant strides in the industry, particularly in the fields of haematology and oncology. PharmaEssentia's flagship product, a novel treatment for essential thrombocythemia, exemplifies its commitment to addressing unmet medical needs with unique, scientifically-backed solutions. With a strong presence in Asia and expanding operations in global markets, PharmaEssentia has established itself as a key player in the biopharmaceutical landscape, recognised for its rigorous research and development efforts. The company continues to focus on delivering high-quality, effective therapies that improve patient outcomes and enhance quality of life.
How does PharmaEssentia Corp's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
PharmaEssentia Corp's score of 24 is lower than 58% of the industry. This can give you a sense of how well the company is doing compared to its peers.
In 2023, PharmaEssentia Corp reported total carbon emissions of approximately 4,374,400 kg CO2e, with Scope 2 emissions from purchased electricity accounting for about 2,905,970 kg CO2e. This marks a slight increase from 2022, when total emissions were approximately 4,264,600 kg CO2e, with Scope 2 emissions at about 3,037,270 kg CO2e. Over the past few years, emissions have fluctuated, with 2021 reporting approximately 4,325,920 kg CO2e and 2020 at about 4,412,060 kg CO2e. PharmaEssentia has not disclosed any Scope 1 emissions data, and there is no reported Scope 3 emissions data for 2023. However, in 2019, the company reported Scope 3 emissions of approximately 669,860 kg CO2e, alongside total emissions of about 4,585,030 kg CO2e. Despite the absence of specific reduction targets or commitments, PharmaEssentia is actively engaged in monitoring and reporting its emissions, as evidenced by its participation in the CDP initiative. The company has not cascaded any emissions data from a parent organization, indicating that its reported figures are independently sourced. Overall, while PharmaEssentia Corp has shown a commitment to transparency in its emissions reporting, further details on reduction initiatives or climate pledges would enhance its sustainability profile.
Access structured emissions data, company-specific emission factors, and source documents
2019 | 2020 | 2021 | 2022 | 2023 | |
---|---|---|---|---|---|
Scope 1 | - | - | - | - | - |
Scope 2 | 3,055,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 |
Scope 3 | 669,860 | - | - | - | - |
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
PharmaEssentia Corp is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.